Board additions are routine governance moves with no immediate financial impact. Monitor Insmed's upcoming pipeline catalysts and quarterly results for fundamental signals — this filing does not change the investment thesis.
Price Chart
Executive Summary
Insmed appointed Paul Hudson (former CEO of Sanofi and Novartis Pharmaceuticals) and Utpal Koppikar (CFO of Verily Health and former CFO of Atara Biotherapeutics) as independent directors, effective October 19, 2026. The appointments add deep biopharma leadership and financial expertise to the board but carry no financial guidance or operational changes — this is a routine governance enhancement.
Key Facts
- Paul Hudson and Utpal Koppikar appointed to the Board effective October 19, 2026
- Hudson serves as Class II director on Compensation Committee; Koppikar serves as Class I director on Audit Committee
- Each director receives an annual cash retainer of $65,000, prorated for the current year
- Hudson receives an additional $12,500 annual retainer for Compensation Committee service; Koppikar receives $12,500 for Audit Committee service
- Each director receives RSUs with a grant date fair value of approximately $585,000, vesting in equal thirds over three years
- No material transactions or arrangements exist between either director and any person regarding their selection
Financial Impact
Total annual director compensation for the two new appointees is approximately $155,000 in cash retainers plus $1,170,000 in RSU grants — immaterial relative to Insmed's market cap.
Risk Factors
- No operational or financial risks disclosed in this filing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-040177 |
| Document: ef20084030_ex99-1.htm | 0001140361-26-040177 |
| Document: 0001140361-26-040177-index-headers.html | 0001140361-26-040177 |
| Document: 0001140361-26-040177-index.html | 0001140361-26-040177 |
| Document: 0001140361-26-040177.txt | 0001140361-26-040177 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | Institutional Cluster | $94.04 | awaiting T+20 | — | $94.96 (+0.98%) |
Oct 20, 2026 7d ago | 8-K | $95.67 | awaiting T+20 | — | $94.96 (−0.74%) |
Oct 5, 2026 22d ago | 8-K | $103.83 | awaiting T+20 | — | $94.96 (−8.54%) |
Aug 19, 2026 9w ago | Insider Cluster | $125.08 $120.00 | ▼ −4.06% | ▼ −4.19% | $94.96 (−24.08%) |
Aug 12, 2026 10w ago | Insider Cluster | $126.33 $129.41 | ▲ +2.44% | ▲ +4.19% | $94.96 (−24.83%) |
Aug 6, 2026 11w ago | 8-K | $132.55 $126.68 | ▼ −4.43% | ▼ −5.03% | $94.96 (−28.36%) |
Jul 24, 2026 13w ago | Institutional Cluster | $106.92 $125.77 | ▲ +17.63% | ▲ +14.00% | $94.96 (−11.19%) |
Jul 21, 2026 14w ago | ANALYST-UPGRADE | $108.62 $128.46 | ▲ +18.27% | ▲ +15.70% | $94.96 (−12.58%) |
Jul 16, 2026 14w ago | 8-K | $107.46 $126.33 | ▲ +17.56% | ▲ +13.94% | $94.96 (−11.63%) |
Jun 26, 2026 17w ago | Insider Cluster | $104.74 $106.92 | ▲ +2.08% | ▲ +2.36% | $94.96 (−9.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers